黑龙江珍宝岛药业发布公告，持股5%以上股东湖州赛瀚履行减持计划，9月10日通过集中竞价减持 48,354股。此前因公司回购注销限制性股票，湖州赛瀚持股比例被动增加。本次权益变动后，其持股降 至47,049,826股，比例降至5%，不再是持股5%以上股东。此次变动不触及要约收购，也不改变公司控 股权。目前减持计划未实施完毕，公司将密切关注进展并督促披露。 ...

Core Points - The 2025 International (Bozhou) Traditional Chinese Medicine Expo and the 41st National (Bozhou) Chinese Herbal Medicine Trade Fair opened in Bozhou City [2] - Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. has been a co-organizer of the expo for seven consecutive years [2] - The president of Bozhou Chinese Herbal Medicine Trading Center, Fang Fuyuan, represented the company at the opening ceremony and accompanied guests during the exhibition [2] Industry Overview - The exhibition area of Bozhou Chinese Herbal Medicine Trading Center includes displays of high-quality medicinal materials from across the country, products from national traditional Chinese medicine enterprises, health products related to flower tea, medicinal ingredients for dietary therapy, and pharmaceutical machinery and packaging equipment [3] - The expo showcases Bozhou's brand image from multiple dimensions [3] - The exhibition highlights the comprehensive business model of the Bozhou Chinese Herbal Medicine Trading Center, covering the entire industry chain of Chinese medicinal materials [2]

Group 1 - The event "Guizhou Medicine Goes Out, Accumulated 'Bo' Development" was held in Bozhou, focusing on linking Guizhou's high-quality traditional Chinese medicine resources with the largest trading market in the world [1] - Over 200 representatives from the governments of Guizhou and Anhui, industry associations, and enterprises attended the event, indicating strong willingness for production and sales connections [1] - The current status, advantageous varieties, and future development plans of Guizhou's traditional Chinese medicine industry were comprehensively introduced during the event [1] Group 2 - A significant promotion of Guizhou's representative enterprises showcased the quality characteristics and industrial advantages of local medicinal materials such as Tianma, Huangjing, Taizishen, and Banxia [1] - The Bozhou Traditional Chinese Medicine Commodity Trading Center's Vice President highlighted the large-scale traditional Chinese medicine trading platform, emphasizing a "six unification" operational model to enhance transaction processes through digital means [1] - A signing ceremony for strategic cooperation units concluded the event, resulting in multiple collaborations between Guizhou and the Bozhou Traditional Chinese Medicine Commodity Trading Center [1] Group 3 - In addition to the promotion event, over 100 Guizhou enterprises participated in a large exhibition at the trading center, showcasing a 2000 square meter exhibition area featuring local medicinal materials and specialty agricultural products [2] - The exhibition included experience zones for Miao and Yao medicine therapies, tea tasting areas, and performances of ethnic dances, enriching the cultural experience at the Bozhou Medicine Expo [2]

证券代码：603567 证券简称：珍宝岛 公告编号：临2025-070 黑龙江珍宝岛药业股份有限公司 关于为全资子公司提供担保进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 （二） 内部决策程序 公司于 2025 年 8 月 11 日召开第五届董事会第二十五次会议，审议并通过了 《关于为全资子公司提供担保的议案》，该议案已经全体董事的过半数董事审议 通过以及出席董事会会议的三分之二以上董事审议通过，董事会同意提请公司 2025 年第二次临时股东会授权公司法定代表人处理在核定担保额度内的担保事 项并签署相关协议。（具体内容详见公司在上海证券交易所网站披露的临 2025-061 号公告）。 | 被担保人名称 | | 黑龙江珍宝岛医药贸易有限公司 | | | --- | --- | --- | --- | | 本次担保金额 | 15,000.00 | 万元 | | | 担保对象 实际为其提供的担保余额 | 34,500.00 | 万元 | | | 是否在前期预计额度内 | 是 | □ ...

Core Insights - The conference emphasizes the modernization and intelligence of the traditional Chinese medicine industry, with a focus on "smart trading" to enhance the supply chain and promote high-quality development [1][3]. Group 1: Industry Development - The conference, hosted by Zhenbao Island Pharmaceutical, highlights the importance of "authentic medicinal materials" as the core of traditional Chinese medicine, which is crucial for the entire industry chain [3]. - Smart trading is identified as a key solution to address issues such as information asymmetry, lack of standardization, and multiple circulation links in the medicinal materials market [3]. - The establishment of a traceable system through smart trading platforms is expected to enhance production standards and incentivize farmers to improve the quality of medicinal materials [3][4]. Group 2: Platform and Technology - The Baizhou Medicinal Materials Trading Center aims to create a "platform + entity" smart market by integrating internet, logistics, quality inspection, and financial services [4]. - The trading center promotes a multi-model, full-chain service approach to reshape trading processes using digital means, providing a smart, convenient, and secure trading experience [4]. - The center has signed cooperation agreements with over 50 entities, marking significant progress in resource integration and standard recognition within the industry [4][5]. Group 3: Future Outlook - Zhenbao Island Pharmaceutical plans to leverage its resource aggregation advantages to strengthen its position as a leading platform in the medicinal materials industry, promoting the transformation and upgrading of the traditional Chinese medicine circulation industry [5]. - The company aims to lead the standardization, branding, and internationalization of authentic medicinal materials in China, driven by ongoing multi-dimensional industry cooperation projects and the growing demand for high-quality resources [5].

Group 1 - The law firm Beijing Lantai Law Firm has been commissioned by Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. to provide legal opinions regarding the company's second extraordinary general meeting of shareholders in 2025 [3][4] - The meeting is scheduled for August 28, 2025, and the law firm will witness the proceedings and provide legal opinions on the relevant matters [5][7] - The law firm confirms that the notice for the meeting was issued in accordance with legal and regulatory requirements, and the actual time, location, and content of the meeting align with the notice [8][9] Group 2 - The meeting was convened by the company's board of directors, and the qualifications of the convenor and attendees were verified to comply with relevant laws and regulations [8][9] - A total of 221 shareholders participated in the meeting, representing 507,558,836 shares with voting rights, which accounts for 53.9384% of the total shares with voting rights [9] - The voting process was conducted in accordance with legal requirements, and the results of the voting were confirmed by the law firm [10] Group 3 - The law firm concluded that the procedures for convening and holding the meeting, as well as the qualifications of the convenor and attendees, were legally valid [10] - The voting procedures and results were also deemed to be legally effective, ensuring compliance with the Company Law and other relevant regulations [10]

Meeting Details - The shareholders' meeting of Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. was held on August 28, 2025, in Harbin [1] - The meeting was convened by the board of directors and chaired by Chairman Fang Tonghua, utilizing a combination of on-site and online voting [1] Voting Results - The non-cumulative voting proposal was approved with 99.7561% of A-share votes in favor, totaling 506,320,936 votes [1] - There were no dissenting votes or abstentions of significant concern [1] Legal Compliance - The meeting's procedures were confirmed to comply with the Company Law and other relevant regulations, ensuring the legality of the convening and voting processes [2]

北京市兰台律师事务所 关于黑龙江珍宝岛药业股份有限公司 2025 年第二次临时股东会的 法 律 意 见 书 兰台意字（2025）第 4745 号 地址：北京市朝阳区曙光西里甲 1 号第三置业大厦 B 座 29 层 电话：（8610）52287799 传真：（8610）58220039 网址：www.lantai.cn 法律意见书 北京市兰台律师事务所 关于黑龙江珍宝岛药业股份有限公司 2025 年第二次临时股东会的 法 律 意 见 书 兰台意字（2025）第 4745 号 对于出具本法律意见书，本所特做如下声明： 1.为出具本法律意见书，本所律师审查了公司提供的有关本次股东会的文 件，同时听取了公司就有关事实的陈述和说明，列席了本次股东会。 2.本所律师根据本法律意见书出具日前发生或存在的事实及有关的法律、行 政法规、规范性文件的规定，就本次股东会所涉及的相关法律问题发表法律意见。 3.在本法律意见书中，本所律师根据《股东会规则》的要求，仅就本次股东 会的召集和召开程序、召集人和出席人员资格、表决程序、表决结果等事项发表 法律意见，不对本次股东会提案的内容以及提案中所涉及的事实和数据的真实 性、准确性等事项发 ...

证券代码：603567 证券简称：珍宝岛 公告编号：临2025-069 黑龙江珍宝岛药业股份有限公司 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 221 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 507,558,836 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 53.9384 | | 份总数的比例（%） | | (四) 表决方式是否符合《公司法》及《公司章程》的规定，股东会主持情况 等。 本次会议由公司董事会召集，公司董事长方同华先生主持。本次会议以现场 和网络投票相结合的方式对股东会通知中列明的事项进行了投票表决，表决方式 符合《公司法》及《公司章程》的规定。 (五) 公司董事和董事会秘书的出席情况 1、 公司在任董事6人，出席5人，独立 ...

Group 1 - The core point of the article is that Zhenbao Island (603567.SH) reported a significant decline in its financial performance for the first half of 2025, with total operating revenue of 714 million yuan, a year-on-year decrease of 57.05% [1] - The net profit attributable to shareholders of the parent company was -78.29 million yuan, compared to a net profit of 393 million yuan in the same period last year [1] - The basic earnings per share were -0.0833 yuan, indicating a loss compared to the previous year's earnings [1]